Clinical Trial

CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

Name: CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma — clinical trial record (NCT06850285)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

The is a prospective, open-label, dose-climbing clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。

Trial Details

NCT Number	NCT06850285
Lead Sponsor	Shanxi Bethune Hospital
Conditions	Lymphoma, B-Cell
Enrollment	15 participants
Start Date	2025-09-05
Primary Completion	2028-06-01 (estimated)
Study Completion	2028-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-02-27